HA
ZBH icon

Harfst & Associates’s Zimmer Biomet ZBH Stock Holding History

Harfst & Associates’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-160
Closed -$18K – 303
2017
Q1 		$18K Buy
+160
New +$18.1K 0.01% 195
2016
Q1 		– Sell
-574
Closed -$57K – 256
2015
Q4 		$57K Sell
574
-422
-42% -$41.3K 0.02% 175
2015
Q3 		$91K Buy
996
+159
+19% +$15.9K 0.04% 137
2015
Q2 		$89K Buy
+837
New +$92.6K 0.05% 131

Other funds holding ZBH

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Harfst & Associates's ZBH Position: Q2 2017 in Review

Harfst & Associates sold out of Zimmer Biomet (ZBH) in Q2 2017, closing a stake of 160 shares — an estimated $18K sold.

Harfst & Associates first reported a position in ZBH in Q2 2015 and held it in 4 quarters. The position peaked at $91K in Q3 2015. 819 funds tracked by Wall St. Rank hold ZBH as of Q2 2017.

  • Harfst & Associates reported no remaining Zimmer Biomet position as of Q2 2017 after selling out during the quarter.
  • Harfst & Associates sold 160 Zimmer Biomet shares in Q2 2017, an estimated $18K.
  • Harfst & Associates first reported a position in Zimmer Biomet in Q2 2015 and held it in 4 quarters.
  • Harfst & Associates's Zimmer Biomet position peaked at $91K in Q3 2015.
  • 819 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2017.

Based on Harfst & Associates's 13F filing for Q2 2017, filed 11 Aug 2017.